Evidence map›Paper›PMID 40182035›Full record

ArticleFrontiers in oncology2025

The immune cell dynamics in the peripheral blood of cHL patients receiving anti-PD1 treatment.

Vanessa Cristaldi, Lodovico Terzi di Bergamo, Lucrezia Patruno, Marinos Kallikourdis, Giada Andrea Cassanmagnago, Francesco Corrado, Eleonora Calabretta, Adalgisa Condoluci, Martina di Trani, Daoud Rahal and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Vanessa CristaldiDepartment of Biomedical Sciences, Humanitas University, Milano, Italy.
Lodovico Terzi di BergamoLaboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
Lucrezia PatrunoDepartment of Informatics, Systems and Communication of the University of Milan-Bicocca, Milan, Italy.
Marinos KallikourdisDepartment of Biomedical Sciences, Humanitas University, Milano, Italy.
Giada Andrea CassanmagnagoDepartment of Biomedical Sciences, Humanitas University, Milano, Italy.
Francesco CorradoDepartment of Oncology and Hematology, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy.
Eleonora CalabrettaDepartment of Oncology and Hematology, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy.
Adalgisa CondoluciLaboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
Martina di TraniDepartment of Biomedical Sciences, Humanitas University, Milano, Italy.
Daoud RahalDepartment of Pathology, IRCCS Humanitas Research Hospital, Milan, Italy.
Gianluca BassoDepartment of Biomedical Sciences, Humanitas University, Milano, Italy.
Clelia PeanoInstitute of Genetics and Biomedical Research, UoS of Milan, National Research Council, Milan, Italy.
Alex GraudenziInstitute of Molecular Bioimaging and Physiology, Consiglio Nazionale delle Ricerche (IBFM-CNR), Milan, Italy.
Marco AntoniottiDepartment of Informatics, Systems and Communication of the University of Milan-Bicocca, Milan, Italy.
Davide RossiLaboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
Carmelo Carlo-StellaDepartment of Biomedical Sciences, Humanitas University, Milano, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Checkpoint blockade therapy (CBT) involving anti-PD1 antibodies represents the standard approach for cHL patients who do not respond to second-line therapy. Nonetheless, only 20% of relapsed/refractory (R/R) cHL patients treated with CBT achieve complete remission. In this study, we extensively examined the immune dynamics in eight R/R cHL patients treated with CBT, consisting of four complete responders (CR) and four experiencing disease progression (PD), by single cell analysis of peripheral blood mononuclear cells (PBMCs). Our unique approach encompassed longitudinal analysis with three time points, providing a comprehensive understanding of the evolving immune responses during anti-PD1 therapy. Through gene expression profiling, we identified a stable and distinctive KLRG1+/FOS+/JUN+/GZMA+/CD8+ T cell phenotype in patients achieving complete responses. This specific CD8+ T cell subset exhibited sustained activation, underscoring its potential pivotal role in mounting an effective immune response against cHL. Furthermore, T cell receptor (TCR) analysis revealed that in responder patients there is clonal expansion between TCR clonotypes specifically in the KLRG1+/FOS+/JUN+/GZMA+/CD8+ T cell subset. Our longitudinal study offers unique insights into the complex immune dynamics of multiply relapsed/highly pre-treated cHL patients undergoing anti-PD1 therapy.

Indexed as

Hodgkin (cHL)immunotherapyrefractorinesssingle-cell analysisTCR - T cell receptor

Identifiers

PMID40182035
PMCPMC11966435

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.